Halozyme Therapeutics, Inc. Third Quarter Financial & Operating Results NASDAQ: HALO November 3, 2025 1 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance and growth rates (including the Company's 2025 financial guidance and longer term financial outlook through 2028 and the assumptions used in deriving such g ...

Second Quarter 2025 Financial Results - Total revenue reached $325.7 million, a 41% increase compared to the second quarter of 2024[32] - Royalty revenue increased by 65% to $205.6 million[32] - Net income was $165.2 million, a 77% increase year-over-year[32] - Adjusted EBITDA was $225.5 million, a 65% increase compared to the same period last year[32] - GAAP diluted EPS increased by 85% to $1.33, while Non-GAAP diluted EPS increased by 69% to $1.54[32] Full Year 2025 Guidance - Total revenue is projected to be between $1.275 billion and $1.355 billion, representing a 26-33% increase[6] - Royalty revenue is expected to be between $825 million and $860 million, a 44-51% increase[6] - Adjusted EBITDA is guided to be between $865 million and $915 million, a 37-45% increase[6] - Non-GAAP diluted EPS is projected to be between $6.00 and $6.40, a 42-51% increase[6] Share Repurchase Program - The company completed a $250 million accelerated share repurchase program[6] - A new $250 million share repurchase program was announced[6]

Financial Performance - Q1 2025 - Total revenue reached $265 million, a 35% increase compared to the same period last year[9] - Royalty revenue increased by 39% to $168 million[9] - GAAP net income was $118 million, a 54% increase[9] - GAAP diluted EPS increased by 55% to $0.93, while non-GAAP diluted EPS increased by 41% to $1.11[9] - Adjusted EBITDA increased by 40% to $162 million[9] Key Products & Growth Drivers - DARZALEX® SC U S market share is approximately 95%[11] - DARZALEX® sales reached $3.2 billion in Q1 2025, a 22% year-over-year increase[12] - Phesgo® sales are projected to reach $3.3 billion in 2028[14], with Q1 2025 revenue at approximately $675 million, a 52% year-over-year increase[15] - VYVGART® & VYVGART® Hytrulo SC are projected for blockbuster growth to approximately $7 billion in 2028[18] Financial Outlook & Capital Allocation - The company announced a new $250 million share repurchase program[10, 37] - The company projects approximately $1 billion of royalty revenue in 2027[31] - Total revenue for 2025 is guided between $1200 million and $1280 million[40]